Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DNLI
stocks logo

DNLI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.764
+14.07%
--
--
-0.772
-1.03%
--
--
-0.790
+9.72%
Estimates Revision
The market is revising Downward the revenue expectations for Denali Therapeutics Inc. (DNLI) for FY2025, with the revenue forecasts being adjusted by -49.65% over the past three months. During the same period, the stock price has changed by 30.33%.
Revenue Estimates for FY2025
Revise Downward
down Image
-49.65%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.54%
In Past 3 Month
Stock Price
Go Up
up Image
+30.33%
In Past 3 Month
Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 31.14 USD with a low forecast of 26.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 31.14 USD with a low forecast of 26.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.110
sliders
Low
26.00
Averages
31.14
High
37.00
Current: 20.110
sliders
Low
26.00
Averages
31.14
High
37.00
BofA
Buy
maintain
$27 -> $26
2025-11-17
Reason
BofA
Price Target
$27 -> $26
2025-11-17
maintain
Buy
Reason
BofA lowered the firm's price target on Denali Therapeutics to $26 from $27 and keeps a Buy rating on the shares. The firm made changes to its model following the company's Q3 update, noting that Denali management highlighted that they continue to engage with the FDA on the ongoing biologics license application review of tividefusp alfa for Hunter syndrome following the recent extension with new target action date of April 5, 2026.
BofA
Tazeen Ahmad
Buy
downgrade
$27 -> $26
2025-11-16
Reason
BofA
Tazeen Ahmad
Price Target
$27 -> $26
2025-11-16
downgrade
Buy
Reason
BofA analyst Tazeen Ahmad lowered the firm's price target on Denali Therapeutics to $26 from $27 and keeps a Buy rating on the shares. The firm updated smid-cap biotech models following the Q3 reports.
BofA
Tazeen Ahmad
Buy
downgrade
$28 -> $27
2025-05-19
Reason
BofA
Tazeen Ahmad
Price Target
$28 -> $27
2025-05-19
downgrade
Buy
Reason
BofA analyst Tazeen Ahmad lowered the firm's price target on Denali Therapeutics to $27 from $28 and keeps a Buy rating on the shares. Denali announced they have completed the biologics license application for tividenofusp alfa for Hunter Syndrome and noted the application was submitted under the accelerated approval path, the analyst tells investors. The firm updated its model for Q1 results, cash and share count and increase op expense estimates in line with trend and slightly pushed its near-term estimates for tivi' as it expects a launch in early 2026, the analyst noted.
Baird
Outperform -> NULL
downgrade
$30 -> $29
2025-05-08
Reason
Baird
Price Target
$30 -> $29
2025-05-08
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Denali Therapeutics to $29 from $30 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the Tivi BLA was submitted and the commercial launch is on track for early 2026.
B. Riley
Mayank Mamtani
Buy
downgrade
$35 -> $30
2025-05-08
Reason
B. Riley
Mayank Mamtani
Price Target
$35 -> $30
2025-05-08
downgrade
Buy
Reason
B. Riley analyst Mayank Mamtani lowered the firm's price target on Denali Therapeutics to $30 from $35 and keeps a Buy rating on the shares following the Q1 report. The firm updated the company's model. FDA-related uncertainty continues to weigh on the stock, but attainment of regulatory and pipeline execution milestones in coming months, alongside visibility into new FDA leadership staff taking form, could bode well for Denali, the analyst tells investors in a research note.
B of A Securities
Tazeen Ahmad
Strong Buy
Maintains
$30 → $28
2025-03-10
Reason
B of A Securities
Tazeen Ahmad
Price Target
$30 → $28
2025-03-10
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Denali Therapeutics Inc (DNLI.O) is -6.40, compared to its 5-year average forward P/E of -13.65. For a more detailed relative valuation and DCF analysis to assess Denali Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.65
Current PE
-6.40
Overvalued PE
-3.57
Undervalued PE
-23.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-10.38
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.59
Undervalued EV/EBITDA
-19.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
70.90
Current PS
0.00
Overvalued PS
116.58
Undervalued PS
25.21
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DNLI News & Events

Events Timeline

(ET)
2025-12-04
07:20:00
Royalty Pharma and Denali Sign $275M Synthetic Royalty Funding Agreement
select
2025-12-04
07:10:00
Denali Therapeutics and Royalty Pharma Announce $275 Million Synthetic Royalty Funding Agreement
select
2025-11-06 (ET)
2025-11-06
16:29:02
Denali's Chief Medical Officer Carole Ho to Leave for Eli Lilly
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-04NASDAQ.COM
Denali and Royalty Pharma Sign $275 Million Royalty Financing Deal

  • Funding Agreement: Denali Therapeutics and Royalty Pharma have entered a $275 million synthetic royalty funding agreement related to the investigational therapy Tividenofusp alfa, aimed at treating mucopolysaccharidosis type II (Hunter syndrome).

  • FDA Review and Payments: The agreement is contingent on Denali obtaining FDA accelerated approval for Tividenofusp alfa, with Royalty Pharma making an initial payment of $200 million and a potential additional $75 million upon European approval by 2029.

  • Royalty Terms: Royalty Pharma will receive a 9.25% royalty on worldwide net sales of Tividenofusp alfa, which will cease once a multiple of 3.0x is reached, or 2.5x if achieved by early 2039.

  • Designations and Market Response: Tividenofusp alfa has received Fast Track and Priority Medicines designations from the FDA and EMA, respectively, and shares of Denali and Royalty Pharma saw slight increases following the announcement.

[object Object]
Preview
7.5
12-04Globenewswire
Royalty Pharma Secures $275M Synthetic Royalty Agreement with Denali for Tividenofusp Alfa
  • Funding Agreement Established: Royalty Pharma has signed a $275 million synthetic royalty funding agreement with Denali based on future net sales of tividenofusp alfa, reflecting strong confidence in this innovative therapy.
  • Accelerated Approval Outlook: The Biologics License Application for tividenofusp alfa is under review by the FDA, with a target date of April 5, 2026, which will significantly bolster Denali's market prospects.
  • Initial Payment Structure: Royalty Pharma will make an initial payment of $200 million at closing and an additional $75 million upon EMA approval of tividenofusp alfa, facilitating Denali's advancement of its development programs.
  • Global Sales Rights: Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa, which is expected to provide a stable cash flow for future revenue growth while supporting Denali's product commercialization efforts.
[object Object]
Preview
7.5
12-04Globenewswire
Denali and Royalty Pharma Announce $275 Million Synthetic Royalty Funding Agreement
  • Funding Agreement Established: Denali Therapeutics has signed a $275 million synthetic royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa, reflecting strong confidence in the market potential of this therapy.
  • Accelerated Approval Process: The Biologics License Application for tividenofusp alfa is under review by the FDA, with a target date for accelerated approval set for April 5, 2026, which will provide Denali with crucial market access opportunities.
  • Clear Use of Funds: This financing will be utilized to advance Denali's development programs, particularly supporting the upcoming launch of tividenofusp alfa, thereby enhancing its competitiveness in the rare disease treatment sector.
  • Future Revenue Assurance: Royalty Pharma will make an additional $75 million payment upon receiving EMA approval and will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa, ensuring a shared revenue stream for both parties moving forward.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Denali Therapeutics Inc (DNLI) stock price today?

The current price of DNLI is 20.11 USD — it has increased 5.84 % in the last trading day.

arrow icon

What is Denali Therapeutics Inc (DNLI)'s business?

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

arrow icon

What is the price predicton of DNLI Stock?

Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 31.14 USD with a low forecast of 26.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?

Denali Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?

Denali Therapeutics Inc. EPS for the last quarter amounts to -0.74 USD, increased 17.46 % YoY.

arrow icon

What changes have occurred in the market's expectations for Denali Therapeutics Inc (DNLI)'s fundamentals?

The market is revising Downward the revenue expectations for Denali Therapeutics Inc. (DNLI) for FY2025, with the revenue forecasts being adjusted by -49.65% over the past three months. During the same period, the stock price has changed by 30.33%.
arrow icon

How many employees does Denali Therapeutics Inc (DNLI). have?

Denali Therapeutics Inc (DNLI) has 422 emplpoyees as of December 05 2025.

arrow icon

What is Denali Therapeutics Inc (DNLI) market cap?

Today DNLI has the market capitalization of 2.95B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free